TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Vildagliptin/Metformin Combination on Markers of Atherosclerosis, Thrombosis, and Inflammation in Diabetics With Coronary Artery Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Type 2 Diabetes Mellitus on oral mono-therapy or diet only treatment~* Stable documented ischemic Heart disease (\>30 days post AMI, CABG or PCI)~* Sub-optimal Hb A1c as defined ≥6.5%~* Age \> 21~* Life expectancy \>1 year~Exclusion Criteria:~* Significant renal impairment (creatinine ≥1.4 mg\\dL females or ≥1.5 mg\\dL males)~* Planned coronary intervention or planed surgical intervention (PCI or CABG)~* Planned surgical intervention~* Recent (\<30 day) acute coronary syndrome (ACS)~* Hypersensitivity to either of the study drug components~* History of lactic acidosis~* Type I diabetes~* Current Hb A1c \>9%~* Current Insulin treatment~* Active treatment with GLP-1 or DPP4i medication~* Hepatic impairment or ALT\\AST elevations beyond X2 upper normal limit or known hepatic failure~* Inability to comply with study protocol~* Active malignancy other than basal cell carcinoma (BCC)~* Clinically advanced congestive heart failure - NYHA III-IV~* Severe left ventricular dysfunction (LVEF\<30%) with NYHA II or any NYHA class with documented recent heart failure decompensation (\<3 months)~* Severe stable cardiac angina CCS III - IV or Unstable angina~* Chronic inflammation (i.e. IBD, Lupus, inflammatory arthritis, rheumatoid arthritis) or chronic infection (i.e. chronic diabetic foot infection)~* Pregnancy, lactation or child-bearing potential

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Vildagliptin+metformin (Type: EXPERIMENTAL): Oral Vildagliptin+metformin combination
- Metformin only (Type: ACTIVE_COMPARATOR): Oral metformin only

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Radiesse® Dermal Filler for Hand Treatment

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Has right and left hands with rating of 2 or 3 on the Merz Hand Grading Scale (MHGS) as determined by a live, masked evaluator~* Is at least 18 years of age~Exclusion Criteria:~* Has history of hypertropic scarring~* Has a known bleeding disorder or receiving medication that will increase the risk of bleeding as the result of injection~* Has a known hypersensitivity to any of the components of Radiesse or local anesthesia~* Has received in past 6 months or plans to receive during the study dermal resurfacing procedure (chemical peel, dermabrasion, ablative laser resurfacing) or non-invasive skin tightening (Thermage®) in the dorsum of the hands~* Has received in past 2 weeks or plans to receive during the study prescription wrinkle therapies, topical steroids, skin irritating topical preparations, or pigmenting agents (self-tanning agents) in the dorsum of the hands~* Has had any dermal fillers or surgery in the dorsum of the hand

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Radiesse® Injectable Dermal Filler (Type: EXPERIMENTAL): Device: Radiesse Dermal Filler mixed with 2% lidocaine-HCl (final concentration: 0.3% lidocaine-HCl)
- Delayed Treatment (Type: ACTIVE_COMPARATOR): Untreated controls crossed over to treatment with Radiesse Dermal Filler mixed with 2% lidocaine-HCl (final concentration: 0.3% lidocaine) at 3 months

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Near Infrared Spectroscopy (NIRS) as Transfusion Indicator in Neurocritical Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Severe traumatic brain injury (Glasgow coma scale \< 9), subarachnoid hemorrhage (Hunt and Hess scale ≥ 3) or intracranial hemorrhage~* Moderate anemia. Hemoglobin levels \> 7 g/dL and \< 10 g/dL~* Hemodynamical stability (mean arterial pressure \> 75 mm Hg)~* Respiratory stability (PaO2 / FiO2 ratio \> 220)~* Expected length of ICU stay \> 3 days~Exclusion Criteria:~* Patient's relatives' refusal to patient's inclusion in the study~* Active bleeding~* Ongoing need for blood products~* Patients necessitating ongoing resuscitation~* End-stage in which death is imminent~* Antecedents of angina or myocardial infarction (poor cardiopulmonary reserve)~* Deficient signal of rSO2 impeding its proper valuation

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- RBCT based on rSO2 value (Type: EXPERIMENTAL): Intervention: In the rSO2 - strategy group, patients will be transfused to attain a post-transfusion rSO2 values higher than 60%.
- RBCT based on hemoglobin level value (Type: ACTIVE_COMPARATOR): Intervention: In the hemoglobin - strategy group, patients will be transfused to reach post-transfusion hemoglobin levels between 8.5 g/dL and 10 g/dL.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pirfenidone, an Antifibrotic and Antiinflammatory Drug

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with established advanced liver disease caused by hepatitis C virus (HCV) chronic infection defined by a positive test for anti-HCV antibodies and detectable serum HCV RNA (Amplicor HCV 2.0 polymerase chain reaction (PCR) assay).~* Sign an informed consent form to allow the collection of liver biopsies before and after treatment.~* No antifibrotic, antiviral or immunosuppressive drugs for at least 6 months before starting pirfenidone therapy.~* No alcohol intake for at least 6 months before nor during Pirfenidone (PFD) treatment.~Exclusion Criteria:~* Patients with clinical contraindications to hepatic biopsy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Pirfenidone (Type: EXPERIMENTAL): Pirfenidone 400 mg capsules, orally administered thrice daily to yield a daily dose of 1200 mg during two years.
- Matched equivalent placebo (Type: PLACEBO_COMPARATOR): Matched equivalent placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of VI-0521 for the Treatment of Obstructive Sleep Apnea / Hypopnea Syndrome in Obese Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Obese adults 30 - 65 years old (inclusive);~* Women of child-bearing potential must be using adequate contraception;~* BMI between 30 and 40 kg/m2 (inclusive);~* Diagnosis of OSA syndrome with Apnea/Hypopnea Index (AHI) of 15 or greater;~* Unwilling or unable to comply with CPAP treatment;~Exclusion Criteria:~* Known allergy or hypersensitivity to phentermine or topiramate;~* Sleep disorder other than OSA syndrome;~* Women who are pregnant, breast feeding, or intend to become pregnant during the study;~* Presence of unstable angina or heart failure corresponding to NYHA functional class III or IV;~* History of myocardial infarction or coronary revascularization within the past year; any history of stroke;~* Presence of any clinically significant abnormality on electrocardiogram;~* Use of any prescription CNS stimulants;~* History of cholecystitis or cholelithiasis unless treated by cholecystectomy;~* History of glaucoma or any past or present use of medications to treat increased intraocular pressure;~* Weight gain or loss of greater than 5 kg, use of a very low-calorie diet, or participation in a formal weight loss program (investigational or otherwise) within the past 3 months;~* Previous bariatric surgery;~* Shift workers or any subjects with a circadian rhythm disorder;~* Professional drivers or commercial pilots;~* History of nephrolithiasis;~* More than one lifetime episode of major depression;~* History of bipolar disorder, obsessive compulsive disorder, borderline personality disorder, psychotic depression, schizophrenia, schizoaffective disorder, or any other psychotic disorder; history of any psychiatric hospitalization;~* History of a seizure disorder; concurrent use of any anticonvulsant drug (other than assigned study drug);

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- VI-0521 (Type: EXPERIMENTAL): 15 mg Phentermine and 92 mg Topiramate
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Toolbox Approach to Obesity Treatment in Primary Care

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. BMI \> 30 kg/m2 and \< 45 kg/m2~2. Any one of the following (weight-related) diagnoses: type 2 diabetes or pre-diabetes, including those treated with glucose lowering medications; hypertension, including patients treated with anti-hypertensive medications; hyperlipidemia, including those treated with lipid lowering agents; atherosclerotic cardiovascular disease, including coronary heart disease, cerebrovascular disease, or peripheral vascular disease; obstructive sleep apnea~3. Visited their primary care provider (PCP) at least twice during the past 12 months, including once in the last 6 months~Exclusion Criteria:~Heart attack or stroke within the past 6 months; cancer treated within the past 5 years, except for non-melanoma skin cancer or localized prostate cancer; other medical contraindications to weight loss (e.g., end-stage renal disease, cirrhosis); active substance abuse; current treatment for bipolar disorder or schizophrenia; discretion of PCP (see below)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Intervention (Type: EXPERIMENTAL): 350 randomly-selected patients at 4 clinics get a toolbox of weight loss options, including self-monitoring tools; education materials; recreation center passes; commercial weight loss program (Weight Watchers); intensive group counseling (Colorado Weigh); meal replacements; and obesity pharmacotherapy. The initial assessment, a computer program, takes diet and exercise history and helps patients choose personal treatment goals. Interested patients get a starter kit with self-monitoring tools and meal replacements. Subjects must show self-monitoring of diet and exercise to get more intensive therapies. Patients pay a $5-$10 co-pay for the therapies. They select a primary intensive therapy, but are able to add/change depending on results, adherence and budget availability.
- Control (Type: NO_INTERVENTION): Registry patients not selected to be offered the toolbox will receive usual care for weight management. Usual care for obesity at DH includes brief weight loss advice provided by PCPs or prescribing of weight loss medication, for which patients pay out of pocket.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Abemaciclib (LY2835219) In Participants With Previously Treated Breast Cancer That Has Spread

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria.~* Have a diagnosis of Hormone Receptor Positive (HR+), Human Epidermal Growth Factor Receptor 2 Negative (HER2-) breast cancer.~* Recurrent, locally advanced, unresectable or metastatic breast cancer with disease progression following anti-estrogen therapy.~* Prior treatment with at least 2 chemotherapy regimens:~  * At least 1 of these regimens must have been administered in the metastatic setting.~ * At least 1 of these regimens must have contained a taxane.~ * No more than 2 prior chemotherapy regimens in the metastatic setting.~* Have a performance status (PS) of 0 to 1 on the Eastern Cooperative Oncology Group scale.~* Have discontinued all previous therapies for cancer.~* Have the presence of measureable disease as defined by Response Evaluation Criteria in Solid Tumors Version 1.1.~Exclusion Criteria:~* Have either a history of central nervous system (CNS) metastasis or evidence of CNS metastasis on the magnetic resonance image of brain obtained at baseline.~* Received prior therapy with another cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitor.~* Have received treatment with a drug that has not received regulatory approval for any indication within 14 or 21 days of the initial dose of study drug.~* Have had major surgery within 14 days of the initial dose of study drug.~* Have a history of any other cancer (except non-melanoma skin cancer or carcinoma in-situ of the cervix).

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Abemaciclib (Type: EXPERIMENTAL): 200 milligrams (mg) abemaciclib given orally once every 12 hours for 28 days (1 cycle). Participants may continue to receive treatment until discontinuation criteria are met.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A 58-Week Safety and Efficacy Trial of Ferric Citrate in Patients With ESRD on Dialysis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Males or non-pregnant, non-breast-feeding females~2. Age ≥18 years~3. On thrice-weekly hemodialysis or on peritoneal dialysis for at least the previous three months prior to Screening~4. Serum phosphorus ≥6.0 mg/dL for study entry~5. Taking less than 3-18 pills/day of current phosphate binder~6. Willing to be discontinued from current phosphate binder(s) and initiated on ferric citrate~7. Willing and able to give informed consent~8. Life expectancy \>1 year~Exclusion Criteria:~1. Parathyroidectomy within six months prior to Screening~2. Actively symptomatic gastrointestinal bleeding or inflammatory bowel disease~3. History of multiple drug allergies or intolerances~4. History of malignancy in the last five years (treated cervical or non-melanomatous skin cancer may be permitted if approved by CCC)~5. Previous intolerance to oral ferric citrate~6. Intolerance to oral iron-containing products~7. Psychiatric disorder that interferes with the patient's ability to comply with the study protocol~8. Inability to tolerate oral drug intake~9. Intolerance to calcium acetate and sevelamer carbonate~10. Any other medical condition that renders the patient unable to or unlikely to complete the trial or that would interfere with optimal participation in the trial or produce significant risk to the patient~11. Receipt of any investigational drug within 30 days of Screening Visit (Visit 0)~12. Inability to cooperate with study personnel or history of noncompliance~13. Unsuitable for this trial per Investigator's clinical judgment.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Active Control (Type: ACTIVE_COMPARATOR): PhosLo (calcium acetate) Renvela (sevelamer carbonate)
- Placebo (Type: PLACEBO_COMPARATOR): Placebo
- KRX-0502 (Ferric Citrate) (Type: EXPERIMENTAL): ferric citrate

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Ultrasound-guided Hyaluronic or Corticosteroid Injections in Patients With Chronic Subacromial Bursitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. shoulder pain for more than 1 month~2. age ≥ 20 years old~3. painful abduction or internal rotation with a visual analog scale (VAS) pain score ≥4~4. the presence of a painful arc of motion or pain at the middle to terminal range of shoulder abduction or internal rotation with a soft end feel~5. tenderness over the subacromial bursa~6. a reduction in pain of ≥40% on active shoulder abduction or internal rotation at the terminal range after injection of 3ml of 1%lidocain into the SASD bursa under ultrasound (US) guidance.~Exclusion Criteria:~1. a history of uncontrolled chronic diseases, e.g., malignant neoplasms, blood dyscrasia, and infection~2. previous surgery of the affected shoulder~3. any evidence of a rotator cuff tear or tendinopathy, demonstrated by positive resistive tests or sonographic findings~4. calcification of the rotator cuff, demonstrated by x-ray or sonographic findings~5. the presence of arthritis, such as inflammatory arthritis (e.g., rheumatoid arthritis, seronegative spondyloarthropathy, or crystal-related arthropathy), osteoarthritis, frozen shoulder, subacromial spurs, or deformity of the acromion~6. the presence of instability of the affected shoulder~7. a previous fracture near the shoulder region~8. the presence of cervical radiculopathy or myelopathy~9. having received a corticosteroid or hyaluronic acid subacromial or shoulder joint injection in the past 3 months

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- corticosteroids SASD injection (Type: EXPERIMENTAL): under US guidance 2ml triamcinolone (1ml/10mg), 0.5ml distilled water and 1ml 1% lidocaine
- hyaluronic acid (ARTZ) SASD injection (Type: EXPERIMENTAL): under US guidance 2.5ml HA (ARTZ, 1% sodium hyaluronate solution, 10mg/mL, molecular weight 0.9x106Da) and 1ml 1% lidocaine
- normal saline SASD injection (Type: PLACEBO_COMPARATOR): under US guidance 2.5ml normal saline and 0.5ml distilled water and 1ml 1% lidocaine

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of IDP-123 Lotion to Tazorac® Cream, in the Treatment of Acne Vulgaris

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Key Inclusion Criteria:~* Male or female at least 12 years of age and older.~* Written and verbal informed consent must be obtained. Subjects less than age of consent must sign an assent for the study and a parent or a legal guardian must sign the informed consent (if subject reaches age of consent during the study they should be re-consented at the next study visit).~* Women of childbearing potential and females that are pre-menses must be willing to practice effective contraception for the duration of the study. (Effective contraception is defined as stabilized on oral contraceptive for at least 3 months, IUD, condom with spermicidal, diaphragm with spermicidal, implant, Nuvaring, injection, transdermal patch or abstinence.) Females on birth control pills must have taken the same type pill for at least three months prior to entering the study and must not change type during the study. Those who have used birth control pills in the past must have discontinued usage at least three months prior to the start of the study. Women who use birth control for acne control only should be excluded.~* Pre-menses females and women of childbearing potential must have a negative urine pregnancy test at the screening and baseline visits.~Key Exclusion Criteria:~* Use of an investigational drug or device within 30 days of enrollment or participation in a research study concurrent with this study;~* Any dermatological conditions on the face that could interfere with clinical evaluations such as acne conglobata, acne fulminans, secondary acne, perioral dermatitis, clinically significant rosacea, gramnegative folliculitis, dermatitis, eczema.~* Any underlying disease(s) or some other dermatological condition of the face that requires the use of interfering topical or systemic therapy or makes evaluations and lesion count inconclusive.~* Subjects with a facial beard or mustache that could interfere with the study assessments.~* Evidence or history of cosmetic-related acne.~* Subject has a history of experiencing significant burning or stinging when applying any facial treatment (eg, make-up, soap, masks, washes, sunscreens, etc) to their face.

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- IDP-123 Lotion (Type: EXPERIMENTAL): Lotion
- Tazorac Cream (Type: ACTIVE_COMPARATOR): Cream
- Vehicle Lotion (Type: ACTIVE_COMPARATOR): Lotion
- Vehicle Cream (Type: ACTIVE_COMPARATOR): Cream

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete